Repurposing Drugs in Oncology (ReDO)—mebendazole as an anti-cancer agent
View/ Open
Author
Pantziarka, Pan
Bouche, Gauthier
Meheus, Lydie
Sukhatme, Vidula
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.3332/ecancer.2014.443Metadata
Show full item recordCitation
Pantziarka, Pan, Gauthier Bouche, Lydie Meheus, Vidula Sukhatme, and Vikas P Sukhatme. 2014. “Repurposing Drugs in Oncology (ReDO)—mebendazole as an anti-cancer agent.” ecancermedicalscience 8 (1): 443. doi:10.3332/ecancer.2014.443. http://dx.doi.org/10.3332/ecancer.2014.443.Abstract
Mebendazole, a well-known anti-helminthic drug in wide clinical use, has anti-cancer properties that have been elucidated in a broad range of pre-clinical studies across a number of different cancer types. Significantly, there are also two case reports of anti-cancer activity in humans. The data are summarised and discussed in relation to suggested mechanisms of action. Based on the evidence presented, it is proposed that mebendazole would synergise with a range of other drugs, including existing chemotherapeutics, and that further exploration of the potential of mebendazole as an anti-cancer therapeutic is warranted. A number of possible combinations with other drugs are discussed in the Appendix.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4096024/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:12717512
Collections
- HMS Scholarly Articles [17922]
Contact administrator regarding this item (to report mistakes or request changes)